trending Market Intelligence /marketintelligence/en/news-insights/trending/sGwhIQQPMN9zDP1zjqj6tw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Biomarin Q2'19 profit declines by 14.1% YOY

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Biomarin Q2'19 profit declines by 14.1% YOY

BioMarin Pharmaceutical Inc. said its second-quarter non-GAAP income amounted to $17.1 million, a decrease of 14.1% from $19.9 million in the prior-year period.

The S&P Global Market intelligence consensus EPS normalized estimate was 19 cents.

Revenues grew on an annual basis to $387.8 million from $372.8 million in the year-ago period.

GAAP net loss increased 122.6% on an annual basis to $37.4 million, or 21 cents per share, from net loss of $16.8 million, or 9 cents per share.

The company, which develops and commercializes treatments for serious and life-threatening diseases, forecasts non-GAAP income in the range of $130 million to $170 million for the full year, steady with the previous guidance.

San Rafael, Calif.-based BioMarin also maintained its 2019 full-year guidance for a GAAP net loss in the range of $45 million to $85 million and expectations of revenue between $1.68 billion and $1.75 billion.